MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
National Research Corporation Interest Expense 2011-2026 | NRC
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -95 K | -34 K | -41 K | 1.21 M | 1.67 M | 1.81 M | 2.09 M | 1.51 M | 82 K | 190 K | 220 K | 305 K | 397 K | 541 K | 629 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 M | -95 K | 699 K |
Quarterly Interest Expense National Research Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.46 M | 1.03 M | 899 K | - | 706 K | 555 K | 605 K | - | -12 K | -2 K | 241 K | - | 288 K | 318 K | 317 K | - | 413 K | 423 K | 432 K | - | 451 K | 450 K | 465 K | - | 510 K | 533 K | 570 K | - | 544 K | 439 K | 8 K | - | 18 K | 23 K | 27 K | - | 38 K | 36 K | 85 K | - | 52 K | 57 K | 63 K | - | 76 K | 78 K | 81 K | - | 91 K | 101 K | 117 K | - | 134 K | 140 K | 142 K | - | 155 K | 156 K | 169 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.46 M | -12 K | 300 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
81 M | $ 110.24 | -2.86 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Waters Corporation
WAT
|
14.3 M | $ 289.16 | -3.79 % | $ 17.2 B | USA |
 |
Exagen
XGN
|
2.34 M | $ 2.68 | -3.94 % | $ 57.8 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.36 | -11.57 % | $ 176 M |  China |
 |
Sotera Health Company
SHC
|
8.55 M | $ 13.13 | -3.03 % | $ 3.73 B | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.16 | 0.87 % | $ 6.32 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
177 M | $ 62.25 | -5.81 % | $ 24.3 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 23.53 | -4.74 % | $ 654 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 159.16 | -3.62 % | $ 7.89 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 195.51 | -1.33 % | $ 21.7 B | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
PerkinElmer
PKI
|
-3.36 M | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 8.7 | -4.92 % | $ 1.89 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 264.2 | -1.56 % | $ 22 B | USA |
 |
Psychemedics Corporation
PMD
|
17 K | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
-1 K | $ 25.97 | -4.52 % | $ 33.7 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 16.78 | -3.95 % | $ 894 M | USA |
 |
Quotient Limited
QTNT
|
2.72 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Syneos Health
SYNH
|
79.3 M | - | - | $ 4.46 B | USA |
 |
Renalytix AI plc
RNLX
|
249 K | - | 5.66 % | $ 22.7 M |  Britain |
 |
VolitionRx Limited
VNRX
|
-233 K | $ 0.2 | 1.87 % | $ 19.2 M |  Singapore |
 |
Bioventus
BVS
|
-1.45 M | $ 8.94 | -3.46 % | $ 596 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Meridian Bioscience
VIVO
|
1.19 M | - | - | $ 1.49 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 181.52 | -3.27 % | $ 129 B | USA |
 |
Surmodics
SRDX
|
310 K | - | - | $ 608 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.29 | -6.54 % | $ 2.3 M | USA |